natgillin/translations-raw huggingface dataset:
rifampicin, because it is contraindicated with boosted protease inhibitors, and rifapentine (medicines to treat some infections such as tuberculosis) products that contain St John’s wort (Hypericum perforatum) (a herbal product used for depression).
rifampicin, budući da je kontraindiciran s pojačanim inhibitorima proteaze i rifapentin (lijekovi za liječenje nekih infekcija poput tuberkuloze) pripravci koji sadrže gospinu travu (Hypericum perforatum) (biljni pripravak koji se koristi za depresiju).
rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),
rifampicin, klaritromicin, telitromicin (antibiotici za liječenje infekcija),
rifampicin, erythromycin , clarithromycin or itraconazole. other treatments for erectile dysfunction.
rifampicin, eritromicin, klaritromicin ili itrakonazol druge lijekove za erektilnu disfunkciju
rifampicin, erythromycin , clarithromycin or itraconazole. other treatments for erectile dysfunction.
rifampicin, eritromicin, klaritromicin ili itrakonazol. druge lijekove za erektilnu disfunkciju.
rifampicin, erythromycin, clarithromycin or itraconazole. other treatments for erectile dysfunction.
rifampicin, eritromicin, klaritromicin ili itrakonazol druge lijekove za erektilnu disfunkciju
rifampicin, erythromycin, clarithromycin or itraconazole. other treatments for erectile dysfunction.
rifampicin, eritromicin, klaritromicin ili itrakonazol. druge lijekove za erektilnu disfunkciju.
rifampicin, rifabutin (antibiotics);
rifampicin, rifapentin (antibiotici);
Rifampicin, rifabutin or isoniazid (used to treat tuberculosis);
rifampicin, rifabutin ili izoniazid (koristi se za liječenje tuberkuloze);
rifampicin, rifabutin or rifapentine, antibiotics used to treat tuberculosis
rifampicin, rifabutin ili rifapentin, antibiotike koji se koriste za liječenje tuberkuloze
rifampicin, rifabutin, used for tuberculosis,
rifampicin, rifabutin za liječenje tuberkuloze,
rifampicin, rifapentine (antibiotics);
rifampicin, rifapentin (antibiotici)
rifampicin, rifapentine (antibiotics);
rifampicin, rifapentin (antibiotici);
rifampicin, rifapentine (medicines to treat some bacterial infections such as tuberculosis)
rifampicin, rifapentin (lijekovi za liječenje nekih bakterijskih infekcija kao što je tuberkuloza)
rifampicin, rifapentine, rifabutin
rifampicin, rifapentin, rifabutin
Rifampicin, St. John’s wort.
Rifampicin, Gospina trava.
rifampicin, used to prevent and treat tuberculosis and other infections
rifampicin, koji se primjenjuje za sprječavanje i liječenje tuberkuloze i drugih infekcija
rifampicin, used to prevent and treat tuberculosis and other infections
rifampicin, primjenjuje se za sprječavanje i liječenje tuberkuloze i drugih infekcija
rifampicin, used to treat tuberculosis or meningitis, herbal preparation containing hypericum perforatum (St John’s wort) used to treat minor to moderate depression.
rifampicin, koji se koristi za liječenje tuberkuloze ili meningitisa, biljni pripravak koji sadrži hypericum perforatum (Gospinu travu) koja se koristi za liječenje blage do umjerene depresije.
rifampicin, used to treat tuberculosis.
rifampicin koriste se za liječenje tuberkuloze;
rifampicin.
Antifungalni lijekovi
Rifampicin/ Rilpivirine
Rifampicin/rilpivirin
Rifampicin/Abacavir
rifampicin/abakavir
Rifampicin/efavirenz (600 mg once daily/600 mg once daily)
(600 mg jedanput na dan /600 mg
Rifampicin/Tenofovir disoproxil fumarate
Rifampicin/Tenofovirdizoproksilfumar at
Rifampicin/Tenofovir disoproxil fumarate (600 mg q.d./300 mg q.d.)
rifamicipin/tenofovirdizoproksil fumarat (600 mg q.d./300 mg q.d.)
Rifampicin:
Rifampicin
Rifampicin: co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily with rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of bosentan by 58%, and this decrease could achieve almost 90% in an individual case.
Rifampicin: istodobna primjena u 9 zdravih osoba kroz 7 dana bosentana 125 mg dvaput dnevno s rifampicinom, jakim induktorom CYP2C9 i CYP3A4, smanjila je koncentracije bosentana u plazmi za 58%, a u pojedinim slučajevima i za gotovo 90%.
Rifampicinf (600 mg single dose)
Rifampicin (jedna doza od 600 mg)
rifampin (used to treat tuberculosis and some other infections)
rifampin (koristi se za liječenje tuberkuloze i nekih drugih infekcija),
rifampin – to treat tuberculosis warfarin – to prevent and treat blood clots forming in the legs, lungs, brain and heart.
rifampicin – za liječenje tuberkuloze varfarin – za sprječavanje i liječenje nastanka krvnih ugrušaka u nogama, plućima, mozgu i srcu.
Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz.
Rifamicinski antibiotici (rifampicin, rifabutin), određeni antikonvulzivi (fenitoin, karbamazepin, fenobarbital, primidon) i efavirenz
Rifapentine
Vorikonazol
rifapentine (antibiotic used to treat infections, including tuberculosis);
rifapentin (antibiotik koji se primjenjuje za liječenje infekcija, uključujući tuberkulozu);
rigid muscles,
krute mišiće.
rigid muscles,
ukočenost mišića,
Rigid plastic film: siliconised polyester
Čvrsta plastična podloga: silikonizirani poliester
rigid posture
ukočeno držanje
Rigors
Tresavica
Rigors
vrućica
rigors (cold shivering sensation) or chills
rigor (osjećaj hladne drhtavice) ili zimica
Rigors, asthenia, pain, infusion site inflammation, injection site oedema, injection site pain, injection site pruritus, injection site swelling, migration of implant
Rigor, astenija, bol, upala mjesta infuzije, edem na mjestu injekcije, bol na mjestu injekcije, svrbež na mjestu injekcije, otok na mjestu injekcije, migracija usatka
rigors, pyrexia, pain and discomfort, fatigue
tresavica, pireksija, bol i nelagoda, umor
Rilpivirine
BID)
rilpivirine
ombitasvir/p
Rilpivirine + Emtricitabine/ Tenofovir disoproxil fumarate n = 550
Rilpivirin + emtricitabin/ tenofovirdizoproksilfu marat n = 550
Rilpivirine + Emtricitabine/ Tenofovir disoproxil fumarate n = 550
Rilpivirin + emtricitabin/teno- fovirdizoproksilfumar at n = 550
Rilpivirine + Emtricitabine/Tenofovir disoproxil fumarate n = 550
Rilpivirin + emtricitabin/tenofovir- dizoproksilfumarat n = 550
Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 RT.
Aktivnost rilpivirina postignuta je nekompetitivnom inhibicijom HIV-1 RT.
Rilpivirine at a dose of 25 mg once daily is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
Rilpivirin u dozi od 25 mg jedanput dnevno najvjerojatnije neće imati klinički važan učinak na izloženost lijekovima koje metaboliziraju enzimi CYP-a.
rilpivirine AUC 1.12 (1.05-1.19) ↔ rilpivirine Cmax 1.04 (0.95-1.13) ↔ rilpivirine Cmin 1.25 (1.16-1.35) ↑ simeprevir AUC 1.06 (0.94-1.19) ↔ simeprevir Cmax 1.10 (0.97-1.26) ↑ simeprevir Cmin 0.96 (0.83-1.11) ↔
rilpivirin AUC 1,12 (1,05-1,19) ↔ rilpivirin Cmax 1,04 (0,95-1,13) ↔ rilpivirin Cmin 1,25 (1,16-1,35)  simeprevir AUC 1,06 (0,94-1,19) ↔ simeprevir Cmax 1,10 (0,97-1,26)  simeprevir Cmin 0,96 (0,83-1,11) ↔
rilpivirine AUC ↑ 13% rilpivirine Cmin NA rilpivirine Cmax ↑ 21%
rilpivirin AUC ↑ 13% rilpivirin Cmin NP rilpivirin Cmax ↑ 21
rilpivirine AUC ↑ 130% rilpivirine Cmin ↑ 178% rilpivirine Cmax ↑ 79% darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔
rilpivirin AUC ↑ 130% rilpivirin Cmin ↑ 178% rilpivirin Cmax ↑ 79% darunavir AUC ↔ darunavir Cmin ↓ 11% darunavir Cmax ↔
rilpivirine AUC ↑ 16%* rilpivirine Cmin ↔* rilpivirine Cmax ↑ 43%*
rilpivirin AUC ↑ 16%* rilpivirin Cmin ↔* rilpivirin Cmax ↑ 43
rilpivirine AUC ↑ 39%
rilpivirin AUC ↑ 39
rilpivirine AUC ↓ 42% rilpivirine Cmin ↓ 48% rilpivirine Cmax ↓ 31%
rilpivirin AUC ↓ 42% rilpivirin Cmin ↓ 48% rilpivirin Cmax ↓ 31
rilpivirine AUC ↓ 76% rilpivirine Cmin NA rilpivirine Cmax ↓ 85%
rilpivirin AUC ↓ 76% rilpivirin Cmin NP rilpivirin Cmax ↓ 85
rilpivirine AUC ↓ 9% rilpivirine Cmin NA rilpivirine Cmax ↔
rilpivirin AUC ↓ 9% rilpivirin Cmin NP rilpivirin Cmax ↔
rilpivirine Cmax ↑ 15%
rilpivirin Cmax ↑ 15
rilpivirine Cmin ↑ 51%
rilpivirin Cmin ↑ 51
Rilpivirine does not inhibit the human cellular DNA polymerases α, β and mitochondrial DNA polymerase γ.
Rilpivirin ne inhibira polimeraze α, β humane stanične DNK i polimerazu γ mitohondrijske DNK.
Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC50 value for HIV-1/IIIB of 0.73 nM (0.27 ng/ml).
Rilpivirin je pokazao aktivnost na laboratorijske sojeve divljeg tipa HIV-1 u akutno zaraženoj liniji T- stanica uz medijan vrijednosti EC50 za HIV-1/IIIB od 0,73 nM (0,27 ng/ml).
Rilpivirine exposure is substantially increased (3-fold) when rilpivirine is given in combination with dasabuvir with ombitasvir/paritaprevir/ritonavir, with a consequent potential for QT-prolongation.
Izloženost rilpivirinu značajno je povećana (3 puta) kada se rilpivirin primjenio u kombinaciji s dasabuvirom s ombitasvirom/paritaprevirom/ritonavirom, uz posljedično moguće produljenje QT- intervala.
Rilpivirine has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Rilpivirin nije ispitan u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C).
Rilpivirine has not been studied in patients with severe hepatic impairment (CPT Score C) (see section 4.2).
Rilpivirin nije ispitivan u pacijenata s teškim oštećenjem jetre (CPT stadij C) (vidjeti dio 4.2).
Rilpivirine hydrochloride has not been studied in patients with severe hepatic impairment (CPT Score C).
Rilpivirinklorid nije ispitivan u pacijenata s teškim oštećenjem jetre (CPT stadij C).
Rilpivirine is primarily metabolised by CYP3A.
Rilpivirin prvenstveno metabolizira putem CYP3A.
Rilpivirine is primarily metabolised by cytochrome P450 (CYP)3A. Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2).
Rilpivirin se primarno metabolizira putem citokroma P450 (CYP)3A. Tako lijekovi koji induciraju ili inhibiraju CYP3A mogu utjecati na klirens rilpivirina (vidjeti dio 5.2).
Rilpivirine is primarily metabolised by cytochrome P450 (CYP3A).
Rilpivirin primarno metabolizira citokrom P450 (CYP3A).
Rilpivirine must not be used in combination with products containing St John’s wort as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3).
Rilpivirin se ne smije primjenjivati u kombinaciji s pripravcima koji sadrže gospinu travu, jer istovremena primjena može rezultirati gubitkom terapijskog učinka rilpivirina (vidjeti dio 4.3).
Rilpivirine resistance mutations were observed in 62.5% (5/8) of subjects with virological failure.
Mutacije povezane s rezistencijom na rilpivirin zabilježene su u 62,5% (5/8) ispitanika s virološkim neuspjehom.
Rilpivirine 
Cτ  22% rilpivirin 
rilpivirine*
rilpivirin
Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Rilpivirin, nenukleozidni inhibitor reverzne transkriptaze (NNRTI).
rilpivirine, darunavir, atazanavir
rilpivirin, darunavir, atazanavir
Rilpivirine-containing regimens
Režimi koji uključuju rilpivirin
Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI resistant HIV-1.
U staničnoj kulturi izabrani su sojevi rezistentni na rilpivirin, počevši s divljim tipom virusa HIV-1 različitog porijekla i podtipa te s virusom HIV-1 rezistentnim na nenukleozidne inhibitore reverzne transkriptaze.
Rilpivirine-treated
Liječeni rilpivirinom
Rilpivirine2
lopinavir /
Rilpivirine:
Emtricitabin:
Rilpivirine:
Rilpivirin
Rilpivirine: AUC: ↑ 12%
Rilpivirin: AUC: ↑ 12
Rilpivirine: AUC: ↑ 13%
Rilpivirin: AUC: ↑ 13
Rilpivirine: AUC: ↑ 130%
Rilpivirin: AUC: ↑ 130
Rilpivirine: AUC: ↑ 16%*
Rilpivirin: AUC: ↑ 16
Rilpivirine: AUC: ↑ 49%
Rilpivirin: AUC: ↑ 49
Rilpivirine: AUC: ↑ 52%
Rilpivirin: AUC: ↑ 52
Rilpivirine: AUC: ↑ 78%
Rilpivirin: AUC: ↑ 78
Rilpivirine: AUC: ↓ 40%
Rilpivirin: AUC: ↓ 40
Rilpivirine: AUC: ↓ 42%
Rilpivirin: AUC: ↓ 42
Rilpivirine: AUC: ↓ 5%
Rilpivirin: AUC: ↓ 5
Rilpivirine: AUC: ↓ 76%
Rilpivirin: AUC: ↓ 76
Rilpivirine: AUC: ↓ 80%
Rilpivirin: AUC: ↓ 80
Rilpivirine: AUC: ↔
Emtricitabin: AUC: ↔
Rilpivirine: AUC: ↔
Rilpivirin: AUC: ↔
Rilpivirine: AUC: ↔* Cmin: ↔* Cmax: ↔*
Rilpivirin: AUC: ↔* Cmin: ↔* Cmax: ↔
rilpivirine: If you are taking rilpivirine, your doctor will monitor you closely.
rilpivirin: ako uzimate rilpivirin, liječnik će vas pažljivo pratiti.
rilpivirine: If your child is taking rilpivirine, your child’s doctor will monitor your child closely.
rilpivirin: Ako uzimate rilpivirin, liječnik će Vas pažljivo pratiti.
Rilutek
2016.
RILUTEK 50 mg film-coated tablets
RILUTEK 50 mg filmom obložene tablete
RILUTEK 50 mg film-coated tablets riluzole
RILUTEK 50 mg filmom obložene tablete riluzol
Rilutek is used to extend the patient’s life or to delay the need for mechanical ventilation.
Rilutek se koristi kako bi se u bolesnika produljilo preživljavanje ili radi odlaganja potrebe za mehaničkom ventilacijom.
Riluzole should be prescribed with care in patients with a history of abnormal liver function, or in patients with slightly elevated serum transaminases (ALT/SGPT; AST/SGOT up to 3 times the upper limit of the normal range (ULN)), bilirubin and/or gamma-glutamyl transferase (GGT) levels.
Riluzol treba propisivati uz oprez bolesnicima s anamnezom poremećaja funkcije jetre kao i bolesnicima s blago povišenim vrijednostima serumskih transaminaza (ALT/SGPT ili AST/SGOT do 3 puta iznad gornje granice normalnih vrijednosti (GGN)), razina bilirubina i/ili gama- glutamiltransferaza (GGT).
Riluzole Zentiva is contraindicated in breast-feeding women (see sections 4.3 and 5.3).
Riluzole Zentiva je kontraindiciran u dojilja (vidjeti dijelove 4.3 i 5.3).
rimiterole and isoprenaline, used to treat respiratory diseases
rimiterol i izoprenalin, koji se koriste za liječenje respiratornih bolesti,
rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine;
rimiterol, izoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-metildopa apomorfin;
Ringer-Lactate solution for injection.
Sljedeće otopine ne smiju se koristiti za rekonstituciju lijeka:
Ringing in ears
Zvonjenje u ušima
ringing in the ear
zvonjava u uhu
ringing in the ear
zvonjenje u uhu
ringing in the ear,
zujanje u uhu,
ringing in the ear,
zujanje u ušima
ringing in the ear,
zujanje u ušima,
ringing in the ears
zujanje u ušima
Ringing in the ears
zvonjava u ušima
ringing in the ears
zvonjenje u ušima
ringing in the ears (normally transient), hearing loss, dizziness
zvonjava u ušima (obično prolazno), gubitak sluha, omaglica
Ringing in the ears (tinnitus)
zujanje u ušima (tinitus)
Ringing in the ears (tinnitus)
zvonjava u ušima (tinitus)
ringing in the ears (tinnitus).
zvonjava u ušima (tinitus);
Ringing in the ears and/or feeling a spinning sensation Stomach pain or discomfort, indigestion, dry mouth, or wind
zvonjenje u ušima i/ili osjećaj vrtnje bol ili nelagoda u trbuhu, loša probava, suha usta ili vjetrovi
ringing in the ears feeling foggy in the head
zujanje u ušima mutan osjećaj u glavi
ringing in the ears*
zvonjava u ušima
ringing in the ears,
zvonjenje u ušima
Ringing in the ears, ear discomfort
zvonjava u ušima, nelagoda u uhu
ringing in the ears, vertigo
zvonjenje u ušima, vrtoglavica
Ringing in the ears;
Zvonjenje u ušima;
Ringing in the ears; vertigo
zvonjenje u ušima, vrtoglavica
ringing in your ears
zvonjava u ušima
ringing noise in ears
zvonjava u ušima
ringing or buzzing in the ears (tinnitus) increase in liver enzymes (seen in blood test)
zvonjenje ili zujanje u ušima (tinitus) povećanje jetrenih enzima (na temelju krvnih pretraga)
ringing or buzzing in the ears (tinnitus), loss of hearing
zvonjava ili zujanje u ušima (tinitus), gubitak sluha
ringing or buzzing in the ears (tinnitus), loss of hearing
zvonjenje ili zujanje u ušima (tinitus), gubitak sluha
Ringing or noise in the ears (tinnitus)
zujanje ili šum u ušima (tinnitus)
ringing sound in the ears, ear pain
zvonjava u ušima, bol u uhu
Ringing sound in your ears
zvonjava u uhu
ringing sound in your ears
zvonjenje u uhu
Ringing sound in your ears
zvonjenje u ušima
Ringing/sound in the ears (tinnitus)
zujanje ili zvukovi u ušima (tinitus)
Ringworm, a fungal infection of the skin (tinea versicolor)
tinea, gljivične infekcije kože (tinea versicolor)
Rinse all the medicine out with warm water.
Isperite oko mlakom vodom.
Rinse all the medicine out with warm water.
Isperite sav lijek toplom vodom.
Rinse and flush procedure, stroke measurement and pump management including troubleshooting
postupke ispiranja, mjerenje udarnog volumena i rukovanje pumpom, uključujući otkrivanje problema
Rinse it all out with warm water.
Isperite oko s mlakom vodom.
Rinse the ampoule with these 2 ml and then transfer the rinsing liquid into the diluent.
Isperite ampulu s tih 2 ml a zatim prebacite tekućinu za ispiranje u razrjeđivač.
Rinse the ampoule with these 2 ml and then transfer the rinsing liquid into the diluent.
Isperite ampulu s tih 2 ml, a zatim prebacite tekućinu za ispiranje u razrjeđivač.
Rinse the cup and syringe with clean water.
Isperite čašicu i štrcaljku čistom vodom.
Rinse the empty syringe after each use into a glass of clean water: 1- Take a glass of clean water
Isperite praznu štrcaljku nakon svake uporabe u čaši čiste vode: 1- Uzmite čašu čiste vode
Rinse the mixing bottle, lid, the syringe and plunger under running water. (The mixing bottle may become stained from the medicine.
Isperite bocu za miješanje, poklopac, štrcaljku i klip pod tekućom vodom. (Boca za miješanje može potamniti od lijeka.
Rinse the mixing bottle, lid, the syringe, and plunger under running water. (The mixing bottle may become stained from the medicine.
Isperite bocu za miješanje, poklopac, štrcaljku i klip pod tekućom vodom. (Boca za miješanje može potamniti od lijeka.
Rinse with water and leave to dry in the air.
Isperite ih vodom i ostavite da se osuše na zraku.
Rinse your eye with warm water.
Isperite oko toplom vodom.
Rinse your hands with large amounts of water
Isperite ruke obilnom količinom vode
Rinse your mouth with water after every dose, and spit it out.
Isperite usta vodom nakon inhaliranja svake doze i ispljunite.
Rinse your mouth with water after you have used the inhaler.
Isperite usta vodom nakon korištenja inhalatora.
Rinsing may reduce the risk of developing oral fungal super-infection during treatment and may also reduce the unpleasant taste associated with colistimethate sodium.
Ispiranje može smanjiti rizik od razvoja gljivičnih superinfekcija u ustima tijekom liječenja i može također smanjiti neugodan okus povezan s kolistimetatnatrijem.
Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or transporters (e.g.
Riocigvat i njegov glavni metabolit nisu inhibitori niti induktori glavnih izooblika CYP-a (uključujući CYP3A4) ili transportere (npr.
Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or transporters (e.g.
Riocigvat i njegov glavni metabolit nisu inhibtori niti induktori glavnih izooblika CYP-a (uključujući CYP3A4) ili transportere (npr.
Riociguat CT (n=19)
Riocigvat CT (n=39)
Riociguat IDT (n=254)
Riocigvat IDT (n=254)
Riociguat is cleared mainly via cytochrome P450-mediated (CYP1A1, CYP3A4, CYP2C8, CYP2J2) oxidative metabolism, direct biliary/faecal excretion of unchanged riociguat and renal excretion of unchanged riociguat via glomerular filtration.
Riocigvat se uglavnom uklanja putem oksidativnog metabolizma posredovanog citokromom P450 (CYP1A1, CYP3A4, CYP2C8, CYP2J2), izravnim izlučivanjem riocigvata u neizmijenjenom obliku putem žuči/stolice i izlučivanjem riocigvata u neizmijenjenom obliku preko bubrega putem glomerularne filtracije.
riociguat is not recommended (see section 4.5);
riocigvatom se ne preporučuje (vidjeti dio 4.5);
Riociguat is rapidly absorbed with maximum concentrations (Cmax) appearing 1-1.5 hours after tablet intake.
Riocivuat se brzo apsorbira i postiže najveću koncentraciju (Cmax) 1-1,5 sati nakon uzimanja tablete.
Riociguat must not be used in patients with a systolic blood pressure below 95 mmHg (see section 4.3).
Riocigvat ne smije se primjenjivati u bolesnika sa sistoličkim krvnim tlakom nižim od 95 mmHg (vidjeti dio 4.3).
Riociguat pharmacokinetics are linear from 0.5 to 2.5 mg.
Farmakokinetika riocigvata je linearna od 0,5 do 2,5 mg.
Riociguat restores the NO-sGC-cGMP pathway resulting in a significant improvement of pulmonary vascular haemodynamics and an increase in exercise ability.
Riocigvat obnavlja put NO-sGC-cGMP, što rezultira značajnim poboljšanjem plućne vaskularne hemodinamike poboljšanjem tolerancije fizičke aktivnosti.
Riociguat should be avoided in patients with a history of serious haemoptysis or who have previously undergone bronchial arterial embolisation.
Riocigvat potrebno je izbjegavati u bolesnika s ozbiljnom hemoptizom u anamnezi ili onih u kojih je prethodno napravljena embolizacija bronhalnih arterija.
Riociguat-treated patients experienced a significant delay in time to clinical worsening versus placebo-treated patients (p = 0.0046; Stratified log-rank test) (see table 6).
U bolesnika liječenih riocigvatom kliničko pogoršanje nastupilo je značajno kasnije naspram bolesnika koji su primali placebo (p=0,0046; stratificirani log-rank test) (vidjeti tablicu 6).
riociguat.
riocigvat
riociguat.
riocigvat.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Riociguat: Pretklinička ispitivanja pokazala su aditivan učinak na sniženje krvnog tlaka kada se PDE5 inhibitori koriste u kombinaciji sa riociguatom.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Riociguat: Pretklinička ispitivanja su pokazala aditivan učinak na snižavanje krvnog tlaka kada su se PDE5 inhibitori koriste u kombinaciji sa riociguatom.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Riociguat: Pretklinička ispitivanja su pokazala aditivan učinak na sniženje krvnog tlaka kada se PDE5 inhibitori koriste u kombinaciji sa riociguatom.
Riom 63963, Clermont Ferrand Cedex 9 France
Riom 63963, Clermont Ferrand Cedex 9 Francuska
rise in body temperature
porast tjelesne temperature.
rise in body temperature.
porast tjelesne temperature.
Rise in body temperature.
povišenja tjelesne temperature.
Rise in white blood cells.
povećanje broja bijelih krvnih stanica.
rise in white blood cells; reduction in blood platelets, which increases risk of bleeding or bruising; headache.
povećani broj bijelih krvnih stanica smanjeni broj trombocita u krvi, zbog čega se može povećati mogućnost pojave krvarenja ili modrica; glavobolja.
rises in the blood levels of liver enzymes (will show up in blood tests)
porast razine jetrenih enzima u krvi (utvrđuje se krvnim pretragama)
rises in the blood levels of liver enzymes (will show up in blood tests)
porast razine jetrenih enzima u krvi (utvrđuje se u krvnim pretragama)
Risk assessment and clinical monitoring are the best indicators of the potential risk of bleeding.
Procjena rizika i klinički nadzor su najbolji pokazatelji potencijalnog rizika za nastanak krvarenja.
Risk associated with increased doses of myelosuppressive medicinal products
Rizik povezan s povećanim dozama mijelosupresijskih lijekova
Risk associated with increased doses of myelosuppressive medicinal products
Rizik povezan s povišenim dozama mijelosupresivnih lijekova
Risk diff. (95% CI)
Razlika rizika (95% CI)
Risk difference (CI95%)
Razlika u riziku (CI95%)
Risk difference (once daily- twice daily)
Razlika u riziku (jedanput na dan-dvaput na dan)
Risk difference (once daily-twice daily)
Razlika u riziku (jedanput na dan- dvaput na dan)
Risk difference (once daily-twice daily)
Razlika u riziku (jedanput na dan-dvaput na dan)
Risk Estimate for HIV-1 Protection:
Procjena rizika za zaštitu od virusa HIV-1: